Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Hou, Hui Qing ^a   Miao, Jun ^b   Feng, Xue Dan ^a   Han, Mei ^a   Song, Xiu Juan ^a   Guo, Li ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b The General Hospital of North China Petroleum Administration Bureau   (China)

Author keywords

Acute inflammatory demyelinating polyneuropathy; Acute motor axonal neuropathy; Guillain Barr syndrome; Intravenous immunoglobulin; Lymphocyte subsets

Indexed keywords

CD19 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ACUTE MOTOR AXONAL NEUROPATHY; ARTICLE; B LYMPHOCYTE; BLOOD ANALYSIS; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTINUOUS INFUSION; CONTROLLED STUDY; FLOW CYTOMETRY; GUILLAIN BARRE SYNDROME; HUGHES SCORE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PATHOGENESIS; SCORING SYSTEM; T LYMPHOCYTE SUBPOPULATION; ADULT; BLOOD; DRUG EFFECTS; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 84965094238     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0202-3     Document Type: Article

References (34)

1. Yuki N: Infectious origins of, and molecular mimicry in, Guillain-Barre and Fisher syndromes. Lancet Infect Dis 2001, 1(1):29-37.
2. Ariga T, Yu RK: Antiglycolipid antibodies in Guillain-Barre syndrome and related diseases: review of clinical features and antibody specificities. J Neurosci Res 2005, 80(1):1-17.
3. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao CY, Yang C, Tian M, Mishu B, Cornblath DR: Guillain-Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 1995, 118(Pt 3):577-595.
4. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA: Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain 2007, 130(Pt 9):2245-2257.
5. Guo L, Hou HQ, Song XJ, Yang JC, Gao CY: Change of T-Lymphocyte subsets in the patients with Gullain-Barre syndrome between pre and posttherapy with intravenous immunoglobulin and its meaning. Chin J Neurol 2008, 41(2):87-90.
6. Dahle C, Vrethem M, Ernerudh J: T lymphocyte subset abnormalities in peripheral blood from patients with the Guillain-Barre syndrome. J Neuroimmunol 1994, 53(2):219-225.
7. Sindern E, Oreja-Guevara C, Raulf-Heimsoth M, Baur X, Malin JP: A longitudinal study of circulating lymphocyte subsets in the peripheral blood during the acute stage of Guillain-Barre syndrome. J Neurol Sci 1997, 151(1):29-34.
8. Hughes RA, Aslan S, Gray IA: Lymphocyte subpopulations and suppressor cell activity in acute polyradiculoneuritis (Guillain-Barre syndrome). Clin Exp Immunol 1983, 51(3):448-454.
9. Lisak RP, Zweiman B, Guerrero F, Moskovitz AR: Circulating T-cell subsets in Guillain-Barre syndrome. J Neuroimmunol 1985, 8(2-3):93-101.
10. Cui LY, Pu CQ, Hu XQ: The diagnosis and treatment guidelines of Guillain-Barre syndrome in China. Chin J Neurol 2010, 43(8):583-586.
11. Asbury AK, Cornblath DR: Assessment of current diagnostic criteria for Guillain-Barre syndrome. Ann Neurol 1990, 27(Suppl):S21-S24.
12. Van den Bergh PY, Pieret F: Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 2004, 29(4):565-574.
13. Van der Meche FG, Van Doorn PA, Meulstee J, Jennekens FG: Diagnostic and classification criteria for the Guillain-Barre syndrome. Eur Neurol 2001, 45(3):133-139.
14. Puri KS, Suresh KR, Gogtay NJ, Thatte UM: Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med 2009, 55(2):131-134.
15. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM: Controlled trial prednisolone in acute polyneuropathy. Lancet 1978, 2(8093):750-753.
16. Peng M, Jia JP: Predictors at nadir of severity on patients with Guillain-Barre syndrome. Chin J Neurol 2004, 37(2):154-157.
17. Asbury AK, Arnason BG, Adams RD: The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969, 48(3):173-215.
18. Hafer-Macko CE, Sheikh KA, Li CY, Ho TW, Cornblath DR, McKhann GM, Asbury AK, Griffin JW: Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39(5):625-635.
19. Feasby TE, Gilbert JJ, Brown WF, Bolton CF, Hahn AF, Koopman WF, Zochodne DW: An acute axonal form of Guillain-Barre polyneuropathy. Brain 1986, 109(Pt 6):1115-1126.
20. Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ: Severe axonal degeneration in acute Guillain-Barre syndrome: evidence of two different mechanisms? J Neurol Sci 1993, 116(2):185-192.
21. Greene SK, Rett MD, Vellozzi C, Li L, Kulldorff M, Marcy SM, Daley MF, Belongia EA, Baxter R, Fireman BH, Jackson ML, Omer SB, Nordin JD, Jin R, Weintraub ES, Vijayadeva V, Lee GM: Guillain-Barre syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the vaccine safety datalink, 2009-2011. PLoS ONE 2013, 8(6):e67185.
22. Souayah N, Yacoub HA, Khan HM, Farhad K, Mehyar LS, Maybodi L, Menkes DL, Qureshi AI: Guillain-Barre syndrome after influenza vaccination in the United States, a report from the CDC/FDA vaccine adverse event reporting system (1990-2009). J Clin Neuromuscul Dis 2012, 14(2):66-71.
23. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M: Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011, 343:d3908.
24. van Doorn PA, Ruts L, Jacobs BC: Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008, 7(10):939-950.
25. Lunn MP, Willison HJ: Diagnosis and treatment in inflammatory neuropathies. J Neurol Neurosurg Psychiatry 2009, 80(3):249-258.
26. Drenthen J, Yuki N, Meulstee J, Maathuis EM, van Doorn PA, Visser GH, Blok JH, Jacobs BC: Guillain-Barre syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry 2011, 82(3):300-305.
27. Magira EE, Papaioakim M, Nachamkin I, Asbury AK, Li CY, Ho TW, Griffin JW, McKhann GM, Monos DS: Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 2003, 170(6):3074-3080.
28. McBreen S, Imlach S, Shirafuji T, Scott GR, Leen C, Bell JE, Simmonds P: Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol 2001, 75(9):4091-4102.
29. Clement LT, Vink PE, Bradley GE: Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate. J Immunol 1990, 145(1):102-108.
30. McNeill L, Cassady RL, Sarkardei S, Cooper JC, Morgan G, Alexander DR: CD45 isoforms in T cell signalling and development. Immunol Lett 2004, 92(1-2):125-134.
31. Matto M, Nuutinen UM, Ropponen A, Myllykangas K, Pelkonen J: CD45RA and RO isoforms have distinct effects on cytokine-and B-cell-receptormediated signalling in human B cells. Scand J Immunol 2005, 61(6):520-528.
32. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius E, Jackson SE, Salmon M, Falciani F, Yong K, Rustin MH, Akbar AN, Vukmanovic-Stejic M: Different proliferative potential and migratory characteristics of human CD4+ regulatory T cells that express either CD45RA or CD45RO. J Immunol 2010, 184(8):4317-4326.
33. Hughes RA, Cornblath DR: Guillain-Barre syndrome. Lancet 2005, 366(9497):1653-1666.
34. Douglas MR, Winer JB: Guillain-Barre syndrome and its treatment. Expert Rev Neurother 2006, 6(10):1569-1574.